Aquestive Therapeutics, Inc. (AQST) shareholders
Close on Nov 17, 2026Market cap $464.39MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Bass Edward P Joint filing with Thru Line L.P. (6.30%) | 9,385,561 | 7.50% | 13G (passive) | Oct 7, 2026 |
| BlackRock, Inc. | 7,992,647 | 6.40% | 13G (passive) amendment | Jun 30, 2026 |
| Roderick Wong Joint filing with RTW Investments, LP (5.20%) | 6,250,000 | 5.20% | 13G (passive) | Sep 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AQST | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bratton Capital Management, L.P. | 9,810,958 | 7.82% | $40.81M | – | 100.00% |
| BlackRock, Inc. | 8,069,373 | 6.43% | $33.57M | +560,302 | 0.00% |
| Rtw Investments, LP | 7,426,471 | 5.92% | $30.89M | – | 0.26% |
| Vanguard Capital Management LLC | 4,584,533 | 3.65% | $19.07M | +140,835 | 0.00% |
| Federated Hermes, Inc. | 3,112,561 | 2.48% | $12.95M | +172,222 | 0.02% |
| State Street Corp | 2,928,020 | 2.33% | $12.18M | +381,829 | 0.00% |
| Geode Capital Management, LLC | 2,622,888 | 2.09% | $10.91M | +214,697 | 0.00% |
| Samsara BioCapital, LLC | 2,500,000 | 1.99% | $10.40M | – | 0.85% |
| Bank Of America Corp /De/ | 1,668,423 | 1.33% | $6.94M | −736,627 | 0.00% |
| Sio Capital Management, LLC | 1,486,175 | 1.18% | $6.18M | −436,712 | 1.02% |
| Propel Bio Management, LLC | 1,442,397 | 1.15% | $6.00M | +731,409 | 3.14% |
| Wasatch Advisors LP | 1,385,843 | 1.10% | $5.77M | +507,527 | 0.04% |
| Two Sigma Investments, LP | 1,281,227 | 1.02% | $5.33M | +141,823 | 0.00% |
| Nuveen, LLC | 1,215,225 | 0.97% | $5.06M | +961,760 | 0.00% |
| Janney Montgomery Scott LLC | 1,106,160 | 0.88% | $4.60M | +17,050 | 0.01% |
| Wells Fargo & Company/Mn | 1,089,037 | 0.87% | $4.53M | +54,393 | 0.00% |
| Commonwealth Equity Services, LLC | 1,046,175 | 0.83% | $4.35M | −36,505 | 0.01% |
| Barclays PLC | 996,665 | 0.79% | $4.15M | +197,502 | 0.00% |
| Blue Owl Capital Holdings LP | 942,932 | 0.75% | $3.92M | −405,000 | 0.59% |
| Northern Trust Corp | 831,151 | 0.66% | $3.46M | +98,647 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 185 | 72M | 57.4% | 24 / 70 | 44 / 18 | 8M | 7M |
| Q1 2026 | 180 | 72M | 57.3% | 49 / 56 | 47 / 45 | 19M | 14M |
| Q4 2025 | 178 | 72M | 57.6% | 47 / 68 | 38 / 21 | 15M | 9M |
| Q3 2025 | 152 | 67M | 53.0% | 48 / 51 | 33 / 11 | 25M | 6M |
| Q2 2025 | 116 | 48M | 38.2% | 15 / 52 | 27 / 19 | 8M | 4M |
| Q1 2025 | 121 | 44M | 35.3% | 28 / 47 | 28 / 19 | 10M | 9M |
| Q4 2024 | 114 | 43M | 34.6% | 21 / 45 | 34 / 22 | 4M | 8M |
| Q3 2024 | 117 | 47M | 37.3% | 38 / 40 | 23 / 17 | 13M | 3M |
| Q2 2024 | 98 | 43M | 33.9% | 32 / 31 | 23 / 31 | 12M | 11M |
| Q1 2024 | 97 | 42M | 33.3% | 51 / 23 | 14 / 9 | 24M | 5M |
| Q4 2023 | 57 | 24M | 19.0% | 15 / 17 | 13 / 5 | 3M | 2M |
| Q3 2023 | 47 | 23M | 18.2% | 6 / 12 | 13 / 13 | 5M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
115 funds held AQST in Q2 2026, 57% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AQST | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,403,709 | 2.71% | $14.16M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,818,547 | 2.25% | $11.73M | 0.01% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 1,389,112 | 1.11% | $5.13M | 0.23% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 1,170,608 | 0.93% | $4.33M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,077,727 | 0.86% | $4.48M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 787,651 | 0.63% | $3.28M | 0.76% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 740,697 | 0.59% | $3.08M | 0.03% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 732,970 | 0.58% | $2.71M | 0.07% | Jul 31, 2026 |
| Wasatch Ultra Growth Fund | 719,415 | 0.57% | $2.99M | 0.65% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 642,672 | 0.51% | $2.67M | 0.02% | Jun 30, 2026 |
| Wasatch Micro Cap Fund | 642,475 | 0.51% | $2.67M | 0.40% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Growth Fund | 530,118 | 0.42% | $1.96M | 0.23% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 524,896 | 0.42% | $2.11M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 469,158 | 0.37% | $1.89M | 0.00% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 374,338 | 0.30% | $1.56M | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daniel Barber | President and CEO, Director | 627,317 | 0.50% | Oct 16, 2026 |
| Matthew W. Davis | Chief Development Officer | 87,500 | 0.07% | Nov 16, 2026 |
| Sherry Korczynski | Chief Commercial Officer | 235,689 | 0.19% | Sep 11, 2026 |
| Peter E. Boyd | Chief People Officer | 284,024 | 0.23% | Sep 10, 2026 |
| Cassie Jung | Chief Operating Officer | 208,833 | 0.17% | Sep 8, 2026 |
| Thomas A. Zalewski | Chief Legal Officer | 100,000 | 0.08% | May 19, 2026 |
| Melina Cioffi | SVP, Regulatory Affairs | 273,200 | 0.22% | May 18, 2026 |
| Lori J. Braender | Corporate Secretary | 231,042 | 0.18% | May 11, 2026 |
| A. Ernest Toth Jr | Chief Financial Officer | 283,460 | 0.23% | May 7, 2026 |
| Matthew J. Greenhawt | Chief Medical Officer | 77,000 | 0.06% | Mar 11, 2026 |
| Carl N. Kraus | Chief Medical Officer | 282,475 | 0.23% | Oct 17, 2025 |
| Stephen Wargacki | Chief Science Officer | 343,552 | 0.27% | Mar 11, 2025 |
| Richard J. Daly | Director | 28,025 | 0.02% | Nov 12, 2026 |
| John Cochran | Director | 161,715 | 0.13% | Oct 23, 2026 |
| Julie Krop | Director | 0 | – | Jun 24, 2026 |
| Timothy E. Morris | Director | – | – | Jun 12, 2026 |
| Abigail L. Jenkins | Director | 0 | – | Jun 12, 2026 |
| Marco Taglietti | Director | – | – | Jun 12, 2026 |
| Gregory B. Brown | Director | 75,085 | 0.06% | Jun 12, 2026 |
| Douglas K. Bratton | 10% owner | 262,204 | 0.21% | Dec 4, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Matthew W. Davis Chief Development Officer | Nov 12, 2026 | Sale(10b5-1 plan) | −7,197 | $3.55 | $25.53K | 87,500 |
| Richard J. Daly Director | Nov 10, 2026 | Buy | +26,825 | $3.54 | $95.09K | 28,025 |
| Richard J. Daly Director | Nov 10, 2026 | Buy | +1,200 | $3.53 | $4.24K | 1,200 |
| Matthew W. Davis Chief Development Officer | Nov 10, 2026 | Tax withholding | −5,303 | $3.52 | $18.67K | 94,697 |
| John Cochran Director | Oct 21, 2026 | Other | +62,229 | – | – | 161,715 |
| Daniel Barber President and CEO, Director | Oct 15, 2026 | Sale(10b5-1 plan) | −25,000 | $4.22 | $105.60K | 627,317 |
| Daniel Barber President and CEO, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −25,000 | $4.82 | $120.50K | 652,317 |
| Sherry Korczynski Chief Commercial Officer | Sep 9, 2026 | Sale(10b5-1 plan) | −8,750 | $5.22 | $45.68K | 235,689 |
| Sherry Korczynski Chief Commercial Officer | Sep 9, 2026 | Option exercise | +8,750 | $2.65 | $23.19K | 244,439 |
| Peter E. Boyd Chief People Officer | Sep 9, 2026 | Option exercise | +2,293 | $0.96 | $2.20K | 284,024 |
| Daniel Barber President and CEO, Director | Sep 8, 2026 | Option exercise | +91,743 | $0.96 | $88.07K | 677,317 |
| Cassie Jung Chief Operating Officer | Sep 3, 2026 | Option exercise | +4,587 | $0.96 | $4.40K | 206,833 |
| Daniel Barber President and CEO, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −25,000 | $4.29 | $107.25K | 585,574 |
| Sherry Korczynski Chief Commercial Officer | Aug 14, 2026 | Tax withholding | −2,714 | $4.25 | $11.53K | 235,689 |
| Daniel Barber President and CEO | Jul 16, 2026 | Sale(10b5-1 plan) | −20,369 | $4.00 | $81.48K | 610,574 |
| Daniel Barber President and CEO | Jul 15, 2026 | Sale(10b5-1 plan) | −4,631 | $4.03 | $18.66K | 630,943 |
| Julie Krop Director | Jun 23, 2026 | Sale(10b5-1 plan) | −25,000 | $5.02 | $125.50K | 0 |
| Julie Krop Director | Jun 23, 2026 | Option exercise | +25,000 | $0.71 | $17.75K | 25,000 |
| Daniel Barber President and CEO | Jun 15, 2026 | Sale(10b5-1 plan) | −25,000 | $4.16 | $104.00K | 635,574 |
| Sherry Korczynski Chief Commercial Officer | Jun 8, 2026 | Tax withholding | −2,714 | – | – | 238,403 |
| Thomas A. Zalewski Chief Legal Officer | May 18, 2026 | Award | +100,000 | – | – | 100,000 |
| Daniel Barber President and CEO | May 15, 2026 | Sale(10b5-1 plan) | −8,257 | $4.29 | $35.42K | 660,574 |
| Melina Cioffi SVP, Regulatory Affairs | May 15, 2026 | Tax withholding | −1,667 | $4.17 | $6.95K | 273,200 |
| Lori J. Braender Corporate Secretary | May 7, 2026 | Tax withholding | −135,690 | $4.23 | $573.97K | 231,042 |
| A. Ernest Toth Jr Chief Financial Officer | May 5, 2026 | Tax withholding | −92,652 | $4.18 | $387.29K | 283,460 |
| Lori J. Braender Corporate Secretary | May 5, 2026 | Tax withholding | −76,147 | $4.18 | $318.29K | 366,732 |
| Peter E. Boyd Chief People Officer | May 5, 2026 | Tax withholding | −56,778 | $4.18 | $237.33K | 281,731 |
| Cassie Jung Chief Operating Officer | May 5, 2026 | Tax withholding | −72,734 | $4.18 | $304.03K | 202,246 |
| Daniel Barber President and CEO | May 5, 2026 | Tax withholding | −335,922 | $4.18 | $1.40M | 668,831 |
| Daniel Barber President and CEO | Mar 10, 2026 | Sale | −180,677 | $4.17 | $753.42K | 1,004,753 |
| Cassie Jung Chief Operating Officer | Mar 10, 2026 | Sale | −45,791 | $4.17 | $190.95K | 274,980 |
| Lori J. Braender Chief Legal Officer | Mar 10, 2026 | Sale | −40,102 | $4.17 | $167.23K | 442,879 |
| A. Ernest Toth Jr Chief Financial Officer | Mar 10, 2026 | Sale | −58,254 | $4.17 | $242.92K | 376,112 |
| Peter E. Boyd Chief People Officer | Mar 10, 2026 | Sale | −29,814 | $4.17 | $124.32K | 338,509 |
| Sherry Korczynski Chief Commercial Officer | Mar 10, 2026 | Sale | −15,741 | $4.17 | $65.64K | 241,117 |
| Melina Cioffi SVP, Regulatory Affairs | Mar 10, 2026 | Sale | −25,311 | $4.17 | $105.55K | 274,867 |
| Daniel Barber President and CEO | Mar 9, 2026 | Award | +262,000 | – | – | 1,185,430 |
| Cassie Jung Chief Operating Officer | Mar 9, 2026 | Award | +80,000 | – | – | 320,771 |
| Lori J. Braender Chief Legal Officer | Mar 9, 2026 | Award | +80,000 | – | – | 482,981 |
| A. Ernest Toth Jr Chief Financial Officer | Mar 9, 2026 | Award | +95,000 | – | – | 434,366 |
| Peter E. Boyd Chief People Officer | Mar 9, 2026 | Award | +80,000 | – | – | 368,323 |
| Matthew W. Davis Chief Development Officer | Mar 9, 2026 | Award | +50,000 | – | – | 100,000 |
| Sherry Korczynski Chief Commercial Officer | Mar 9, 2026 | Award | +75,000 | – | – | 256,858 |
| Melina Cioffi SVP, Regulatory Affairs | Mar 9, 2026 | Award | +100,000 | – | – | 300,178 |
| Matthew J. Greenhawt Chief Medical Officer | Mar 9, 2026 | Award | +75,000 | – | – | 75,000 |
| Peter E. Boyd Chief People Officer | Dec 4, 2025 | Award | +20,000 | – | – | 288,323 |
| Melina Cioffi SVP, Regulatory Affairs | Dec 2, 2025 | Tax withholding | −2,083 | $5.93 | $12.35K | 200,178 |
| Matthew W. Davis Chief Development Officer | Nov 10, 2025 | Award | +50,000 | – | – | 50,000 |
| Cassie Jung Chief Operating Officer | Oct 15, 2025 | Option exercise | +25,000 | $3.10 | $77.50K | 308,346 |
| Cassie Jung Chief Operating Officer | Oct 15, 2025 | Sale(10b5-1 plan) | −67,575 | $7.01 | $473.70K | 240,771 |
| Peter E. Boyd See Remarks | Oct 15, 2025 | Sale(10b5-1 plan) | −10,000 | $7.00 | $70.00K | 268,323 |
| Carl N. Kraus Chief Medical Officer | Oct 15, 2025 | Sale(10b5-1 plan) | −20,272 | $7.00 | $141.90K | 282,475 |
| Daniel Barber President and CEO, Director | Sep 26, 2025 | Sale(10b5-1 plan) | −91,343 | $6.03 | $550.80K | 923,430 |
| Peter E. Boyd See Remarks | Sep 26, 2025 | Sale(10b5-1 plan) | −10,000 | $6.30 | $63.00K | 278,323 |
| Daniel Barber President and CEO, Director | Sep 19, 2025 | Sale(10b5-1 plan) | −400 | $6.00 | $2.40K | 1,014,773 |
| Peter E. Boyd See Remarks | Sep 5, 2025 | Sale(10b5-1 plan) | −15,000 | $5.30 | $79.50K | 288,323 |
| Cassie Jung Chief Operating Officer | Sep 4, 2025 | Option exercise | +25,000 | $0.71 | $17.75K | 345,526 |
| Cassie Jung Chief Operating Officer | Sep 4, 2025 | Sale(10b5-1 plan) | −62,180 | $5.00 | $310.90K | 283,346 |
| Cassie Jung Chief Operating Officer | Sep 4, 2025 | Option exercise | +25,000 | $3.15 | $78.75K | 320,526 |
| Sherry Korczynski Chief Commercial Officer | Aug 14, 2025 | Award | +25,000 | – | – | 181,858 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aquestive Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 30,415 shares on Sep 4, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Daniel Barber Director, Officer | Sep 15, 2026 | 50,000 | $244.00K | Sep 15, 2026 | Restricted Stock Units |
| Sherry Korczynski Officer | Sep 9, 2026 | 8,750 | $45.59K | Sep 9, 2026 | Exercise of Stock Options |
| Daniel Barber Officer | Aug 17, 2026 | 25,000 | $106.25K | Aug 17, 2026 | Restricted Stock Units |
| Daniel Barber Officer | Jul 15, 2026 | 25,000 | $101.00K | Jul 15, 2026 | Restricted Stock Units |
| Julie Krop Director | Jun 23, 2026 | 25,000 | $118.00K | Jun 23, 2026 | Exercise of Stock Options |
| Daniel Barber Officer | Jun 15, 2026 | 25,000 | $104.25K | Jun 15, 2026 | Restricted Stock Units |
| Daniel Barber Officer | May 15, 2026 | 8,257 | $39.06K | May 15, 2026 | Restricted Stock Units |
| Carl N. Kraus Affiliate | Nov 17, 2025 | 53,100 | $286.21K | Nov 17, 2025 | RSU Vesting |
| Peter E. Boyd Officer | Oct 15, 2025 | 10,000 | $70.00K | Oct 15, 2025 | Stock Option |
| Carl N. Kraus Officer | Oct 15, 2025 | 40,544 | $278.94K | Oct 15, 2025 | RSU Vesting |
| Cassie Jung Officer | Oct 15, 2025 | 67,575 | $464.92K | Oct 15, 2025 | Exercise of Stock Options |
| Peter E. Boyd Officer | Sep 29, 2025 | 10,000 | $63.00K | Sep 26, 2025 | Stock Option |
| Daniel Barber Director, Officer | Sep 26, 2025 | 91,343 | $480.46K | Sep 26, 2025 | Private Acquisition from Issuer or an Affiliate |
| Daniel Barber Officer | Sep 19, 2025 | 400 | $1.98K | Sep 19, 2025 | Exercise of Stock Options |
| Peter E. Boyd Officer | Sep 5, 2025 | 15,000 | $79.50K | Sep 5, 2025 | Stock Option |
See a number that looks wrong?